Sep 17, 2025 • Motley Fool
SOMEWHAT-BULLISH
5 Best High-Yield Dividend Stocks to Buy Now
These five dividend stocks yield between 3.5% and 7.1%, but more importantly, they have the cash flows and business models to keep paying through the next downturn.
Aug 22, 2025 • Benzinga
SOMEWHAT-BULLISH
What's Going On With Takeda Stock On Friday? - Takeda Pharmaceutical Co ( NYSE:TAK )
Dawnzera is priced at $57,462 per dose, with peak annual sales estimated at $509 million by 2032. Takeda's Takhzyro sales rose 3.7% to 55.1 billion yen in Q2 2025 despite rising competition. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here →
Aug 21, 2025 • Benzinga
NEUTRAL
Why Is Ionis Pharma Stock Gaining Thursday? - Ionis Pharmaceuticals ( NASDAQ:IONS )
Dawnzera cut monthly HAE attacks by 81% vs placebo in Phase 3, with up to 87% reduction after second dose. Patients switching from Takhzyro or Orladeyo saw a 62% lower HAE attack rate with Dawnzera. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here →
Aug 11, 2025 • Benzinga
NEUTRAL
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors - KalVista Pharmaceuticals ( NASDAQ:KALV ) , Metagenomi ( NASDAQ:MGX )
EMERYVILLE, Calif., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Metagenomi, Inc. MGX ( the "Company" ) , a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to ...
Aug 04, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
CORAL GABLES, Fla., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) today announced the appointment of Daniel Curran, MD, to its Board of Directors.
Jul 30, 2025 • Benzinga
NEUTRAL
Why Is Takeda Pharma Stock Falling On Wednesday? - Takeda Pharmaceutical Co ( NYSE:TAK )
Q1 profit rose 30% Y/Y to ¥124.2 billion ( $834 million ) ; EPS of $0.52 beat estimates. Vyvanse U.S. sales dropped 47% to ¥57.9 billion; Takhzyro, IG, Adcetris saw gains. Missed the rally? Learn exactly where the next leaders are emerging here.